NovaScan: Funding, Investors & Team (Sep 2026)
NovaScan provides diagnostic products that apply bioelectrical impedance to assess tissue characteristics relevant to cancer detection. Its MarginScan device performs ex vivo and in vivo margin evaluation by generating immediate electrical measurements during clinical procedures. The nsCanary tool examines biopsy cores directly after sampling to indicate whether malignant tissue is present. NovaScan also uses machine-learning models to interpret impedance signatures and distinguish cancerous from non-cancerous tissue. These products are designed to support clinical decision-making through rapid, instrument-based analysis.
NovaScan has raised $4.4M across 2 funding rounds on record, the most recent an undisclosed round of $670k announced in May 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NovaScan Company Profile and Key Stats
Latest funding round on record: May 2026.
NovaScan Funding Rounds
NovaScan raised $3.7M in an undisclosed round announced in Nov 2025.
6 months later, an undisclosed round of $670k was announced in May 2026.
NovaScan Founders and Leadership Team
Contact details for the NovaScan team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →NovaScan Funding Compared to Other Biotechnology Startups
NovaScan's latest round of $670k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NovaScan in Biotechnology and Chicago
Companies Similar to NovaScan
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
NovaScan Funding FAQs
What does NovaScan do?
NovaScan provides diagnostic products that apply bioelectrical impedance to assess tissue characteristics relevant to cancer detection. Its MarginScan device performs ex vivo and in vivo margin evaluation by generating immediate electrical measurements during clinical procedures. The nsCanary tool examines biopsy cores directly after sampling to indicate whether malignant tissue is present. NovaScan also uses machine-learning models to interpret impedance signatures and distinguish cancerous from non-cancerous tissue. These products are designed to support clinical decision-making through rapid, instrument-based analysis.
How much funding has NovaScan raised?
NovaScan has raised $4.4M across 2 rounds on record. The most recent is an undisclosed round of $670k announced in May 2026.
When did NovaScan last raise funding?
NovaScan's most recent funding round on record is an undisclosed round of $670k, announced in May 2026.
Who founded NovaScan?
FundedIQ lists Craig Davis (Founder), William Gregory (Founder) at NovaScan.
Where is NovaScan headquartered?
NovaScan is based in Chicago, Illinois, United States.
How many employees does NovaScan have?
NovaScan is in the 1-10 employee band.
How does NovaScan's funding compare to other Biotechnology startups?
NovaScan's latest round of $670k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's NovaScan Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NovaScan is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.